Clinical Trials
4
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
2
50.0%
Not yet recruiting
1
25.0%
Unknown
1
25.0%
No approval data available
- The ChAdOx1 RVF vaccine candidate, developed using the same platform as the Oxford-AstraZeneca COVID-19 vaccine, has begun Phase II clinical trials in Kenya with 240 healthy adult participants. - Phase I trials demonstrated the vaccine was safe and well-tolerated, eliciting high levels of neutralizing antibodies that block viral infection, with medium and high doses showing the strongest immune responses. - This represents the most advanced stage of testing for Rift Valley fever vaccines in an outbreak-affected region, addressing a critical unmet medical need as no vaccines are currently licensed for human use. - The disease affects vulnerable pastoral communities through contact with infected livestock or mosquito bites, with severe cases causing mortality rates up to 50% and potential for climate-driven spread.
- The BOHEMIA trial, the largest study on ivermectin for malaria to date, demonstrated a 26% reduction in new malaria infections when administered alongside standard bed nets in Kenya. - Over 20,000 participants in Kwale County, Kenya received monthly ivermectin doses for three consecutive months, showing significant malaria reduction with only mild, transient side effects. - The World Health Organization's vector control advisory group has reviewed the findings and recommended further studies, marking a potential breakthrough in malaria control strategies. - Beyond malaria prevention, ivermectin treatment provided additional benefits including reduced prevalence of scabies, head lice, and bed bugs in treated communities.
- CEPI is funding Phase II clinical trials in Kenya for the ChAdOx1 RVF vaccine against Rift Valley fever, following promising Phase I results. - The trial will involve 240 healthy adults, assessing the vaccine's safety and ability to stimulate an immune response against the disease. - ChAdOx1 RVF uses the same platform as the Oxford-AstraZeneca COVID-19 vaccine and has shown potential for both human and animal health. - Rift Valley fever is a mosquito-borne disease that disproportionately affects vulnerable communities, with no currently licensed human vaccines.
